Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending February 2014. The report details a specific share repurchase transaction executed on February 12, 2014, in accordance with shareholder authority granted at the Annual General Meeting on May 1, 2013.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure and share repurchase activity.
- Shares Purchased: 242,500 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,655.50 pence per share; lowest price paid was 1,638.75 pence per share.
- Treasury Holdings (Settled): 488,327,913 shares, representing 9.14% of total issued share capital.
- Treasury Holdings (Including Unsettled): 488,666,169 shares, representing 10.06% of total voting rights.
- Shares in Issue (Excluding Treasury): 4,856,655,006 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 242,500 shares on February 12, 2014. Consequently, the percentage of total voting rights held in Treasury increased to 10.06% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a routine disclosure of a share buyback transaction compliant with the Financial Conduct Authority's Disclosure and Transparency Rules.
Key Facts for Investor Verification
- Verify the total number of shares held in Treasury (488,327,913 settled) against the company's latest capitalization table.
- Confirm the percentage of total voting rights held in Treasury (10.06% including unsettled shares) to assess potential dilution or concentration effects.
- Note that the 4,856,655,006 shares in issue (excluding treasury) serve as the denominator for shareholder notification thresholds under FCA rules.